Home > Journals > International Angiology > Past Issues > Articles online first > International Angiology 2021 Mar 19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

International Angiology 2021 Mar 19

DOI: 10.23736/S0392-9590.21.04632-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

PCSK9 inhibition, LDL and lipopolysaccharides: a complex and “dangerous” relationship

Raimondo FEMINÓ 1, Giovanni FEMINÓ 2, Attilio CAVEZZI 3 , Emidio TROIANI 4

1 Anesthesia and Intensive Care Unit, Department of General and Specialist Surgeries, A.O.U. Policlinico di Modena, Modena, Italy; 2 Euro Medical Center Srl, Divisione Immunologia, Florence, Italy; 3 Eurocenter Venalinfa, San Benedetto del Tronto, Ascoli Piceno, Italy; 4 Cardiology Unit, State Hospital, Social Security Institute, Cailungo, Republic of San Marino


PDF


Literature concerning the causative factors of atherosclerotic cardiovascular disease shows complex and sometimes contrasting evidence. Most guidelines suggest a strategy aimed at lowering circulating low density lipoproteins (LDL) and ApoB lipoprotein levels. The use of statins and of cholesteryl ester transfer protein inhibitors has led to a number of controversial outcomes, generating a certain degree of concern about the real efficacy and especially safety of these drugs. Literature data show that the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors results in a dramatic reduction of various markers of lipid metabolism (namely LDL); however, several critical scientific papers have questioned the value, the need and especially the safety of these innovative drugs. LDL are a protective factor against lipopolysaccharides and other microbial derivatives. Similarly, these Gram negative bacteria-derived compounds have been identified as probable culprits of cardiovascular atherogenesis; moreover, lipopolysaccharides increase hepatic synthesis of PCSK9, as defense mechanism. This enzyme modulates LDL receptors level in the liver, as well as in other organs, such as adrenal gland and reproductive organs. Hence, PCSK9 inhibition may influence glucocorticoid secretion and fertility. Lastly, the consequent reduction of circulating LDL may relevantly hindrance immune system and favor lipopolysaccharides diffusion.


KEY WORDS: PCSK9 inhibitors, Lipopolysaccharides, Low Density Lipoproteins (LDL), Statins,
Cardiovascular Disease

top of page